| Literature DB >> 19233632 |
Jon Roffey1, Carine Rosse, Mark Linch, Andrew Hibbert, Neil Q McDonald, Peter J Parker.
Abstract
Intervention in protein kinase C (PKC) has a chequered history, partly because of the poor selectivity of many inhibitors and partly a reflection of the sometimes antagonistic action of related PKC isoforms. Recent advances in targeting PKC isoforms have come from structural work on isolated kinase domains that have provided opportunities to drive selectivity through structure-based avenues. The promise of isoform selective inhibitors and the rationale for their development are discussed in the broader context of the PKC inhibitor arsenal.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19233632 DOI： 10.1016/j.ceb.2009.01.019
Source DB: PubMed Journal: Curr Opin Cell Biol ISSN： 0955-0674 Impact factor: 8.382